Annual CFF
-$148.72 M
-$131.44 M-760.47%
December 31, 2023
Summary
- As of February 7, 2025, CORT annual cash flow from financing activities is -$148.72 million, with the most recent change of -$131.44 million (-760.47%) on December 31, 2023.
- During the last 3 years, CORT annual CFF has fallen by -$160.94 million (-1317.64%).
- CORT annual CFF is now -266.04% below its all-time high of $89.57 million, reached on December 31, 2012.
Performance
CORT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$21.09 M
-$18.94 M-881.02%
September 30, 2024
Summary
- As of February 7, 2025, CORT quarterly cash flow from financing activities is -$21.09 million, with the most recent change of -$18.94 million (-881.02%) on September 30, 2024.
- Over the past year, CORT quarterly CFF has dropped by -$20.55 million (-3784.35%).
- CORT quarterly CFF is now -127.75% below its all-time high of $76.01 million, reached on September 30, 2012.
Performance
CORT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$23.02 M
-$17.18 M-293.96%
September 30, 2024
Summary
- As of February 7, 2025, CORT TTM cash flow from financing activities is -$23.02 million, with the most recent change of -$17.18 million (-293.96%) on September 30, 2024.
- Over the past year, CORT TTM CFF has increased by +$126.43 million (+84.60%).
- CORT TTM CFF is now -125.70% below its all-time high of $89.57 million, reached on December 31, 2012.
Performance
CORT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
CORT Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -760.5% | -3784.3% | +84.6% |
| 3 y3 years | -1317.6% | -10000.0% | -33.2% |
| 5 y5 years | -937.5% | -10000.0% | -33.2% |
CORT Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -760.5% | +50.9% | -2853.5% | +89.8% | -294.0% | +92.4% |
| 5 y | 5-year | -1317.6% | +50.9% | -410.0% | +89.8% | -280.8% | +92.4% |
| alltime | all time | -266.0% | +50.9% | -127.8% | +89.8% | -125.7% | +92.4% |
Corcept Therapeutics Incorporated Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$21.09 M(+881.0%) | -$23.02 M(+294.0%) |
| Jun 2024 | - | -$2.15 M(+295.9%) | -$5.84 M(-96.1%) |
| Mar 2024 | - | -$543.00 K(-170.9%) | -$149.45 M(+0.5%) |
| Dec 2023 | -$148.72 M(+760.5%) | $766.00 K(-119.6%) | -$148.72 M(-0.6%) |
| Sep 2023 | - | -$3.92 M(-97.3%) | -$149.55 M(-6.3%) |
| Jun 2023 | - | -$145.75 M(<-9900.0%) | -$159.59 M(+861.6%) |
| Mar 2023 | - | $181.00 K(-396.7%) | -$16.60 M(-4.0%) |
| Dec 2022 | -$17.28 M(-94.3%) | -$61.00 K(-99.6%) | -$17.28 M(-92.3%) |
| Sep 2022 | - | -$13.96 M(+406.6%) | -$224.19 M(-4.1%) |
| Jun 2022 | - | -$2.76 M(+444.7%) | -$233.87 M(-9.1%) |
| Mar 2022 | - | -$506.00 K(-99.8%) | -$257.15 M(-15.0%) |
| Dec 2021 | -$302.59 M(-2577.4%) | -$206.97 M(+775.4%) | -$302.59 M(+214.3%) |
| Sep 2021 | - | -$23.64 M(-9.2%) | -$96.28 M(+44.2%) |
| Jun 2021 | - | -$26.03 M(-43.3%) | -$66.77 M(+96.8%) |
| Mar 2021 | - | -$45.95 M(+6851.1%) | -$33.94 M(-377.9%) |
| Dec 2020 | $12.21 M(-142.6%) | -$661.00 K(-111.3%) | $12.21 M(-4.1%) |
| Sep 2020 | - | $5.87 M(-13.8%) | $12.73 M(+33.2%) |
| Jun 2020 | - | $6.80 M(+3219.0%) | $9.56 M(-172.7%) |
| Mar 2020 | - | $205.00 K(-242.4%) | -$13.15 M(-54.1%) |
| Dec 2019 | -$28.64 M(+99.8%) | -$144.00 K(-105.3%) | -$28.64 M(-29.3%) |
| Sep 2019 | - | $2.70 M(-116.9%) | -$40.53 M(-21.3%) |
| Jun 2019 | - | -$15.91 M(+4.0%) | -$51.50 M(+63.2%) |
| Mar 2019 | - | -$15.29 M(+27.1%) | -$31.55 M(+120.1%) |
| Dec 2018 | -$14.34 M(+80.2%) | -$12.03 M(+45.5%) | -$14.34 M(-5550.6%) |
| Sep 2018 | - | -$8.27 M(-304.5%) | $263.00 K(-96.1%) |
| Jun 2018 | - | $4.04 M(+110.4%) | $6.69 M(-388.1%) |
| Mar 2018 | - | $1.92 M(-25.1%) | -$2.32 M(-70.8%) |
| Dec 2017 | -$7.95 M(+12.1%) | $2.57 M(-239.4%) | -$7.95 M(-29.9%) |
| Sep 2017 | - | -$1.84 M(-63.0%) | -$11.34 M(-7.6%) |
| Jun 2017 | - | -$4.97 M(+34.1%) | -$12.27 M(+56.6%) |
| Mar 2017 | - | -$3.71 M(+350.5%) | -$7.84 M(+10.5%) |
| Dec 2016 | -$7.10 M(-154.3%) | -$823.00 K(-70.3%) | -$7.10 M(+9.7%) |
| Sep 2016 | - | -$2.77 M(+414.7%) | -$6.47 M(+24.9%) |
| Jun 2016 | - | -$538.00 K(-81.9%) | -$5.18 M(-4.2%) |
| Mar 2016 | - | -$2.97 M(+1421.0%) | -$5.41 M(-141.4%) |
| Dec 2015 | $13.07 M(-524.6%) | -$195.00 K(-86.8%) | $13.07 M(+7.7%) |
| Sep 2015 | - | -$1.48 M(+93.3%) | $12.14 M(-1.9%) |
| Jun 2015 | - | -$766.00 K(-104.9%) | $12.37 M(-1.2%) |
| Mar 2015 | - | $15.52 M(-1474.3%) | $12.53 M(-506.8%) |
| Dec 2014 | -$3.08 M(+217.4%) | -$1.13 M(-9.6%) | -$3.08 M(+21.1%) |
| Sep 2014 | - | -$1.25 M(+104.1%) | -$2.54 M(+52.1%) |
| Jun 2014 | - | -$612.00 K(+587.6%) | -$1.67 M(+57.8%) |
| Mar 2014 | - | -$89.00 K(-85.0%) | -$1.06 M(+9.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$970.00 K(-101.1%) | -$592.00 K(+56.6%) | -$970.00 K(+457.5%) |
| Sep 2013 | - | -$378.00 K(<-9900.0%) | -$174.00 K(-100.2%) |
| Jun 2013 | - | $0.00(0.0%) | $76.21 M(-0.3%) |
| Mar 2013 | - | $0.00(-100.0%) | $76.41 M(-14.7%) |
| Dec 2012 | $89.57 M(+110.8%) | $204.00 K(-99.7%) | $89.57 M(+0.2%) |
| Sep 2012 | - | $76.01 M(>+9900.0%) | $89.41 M(+553.5%) |
| Jun 2012 | - | $198.00 K(-98.5%) | $13.68 M(-0.3%) |
| Mar 2012 | - | $13.16 M(>+9900.0%) | $13.72 M(-67.7%) |
| Dec 2011 | $42.48 M(+84.7%) | $45.00 K(-84.1%) | $42.48 M(-2.3%) |
| Sep 2011 | - | $283.00 K(+19.9%) | $43.49 M(+0.6%) |
| Jun 2011 | - | $236.00 K(-99.4%) | $43.23 M(-32.8%) |
| Mar 2011 | - | $41.92 M(+3865.8%) | $64.35 M(+179.8%) |
| Dec 2010 | $23.00 M(-2.2%) | $1.06 M(+6117.6%) | $23.00 M(-41.7%) |
| Sep 2010 | - | $17.00 K(-99.9%) | $39.47 M(+0.1%) |
| Jun 2010 | - | $21.35 M(+3659.5%) | $39.45 M(+118.0%) |
| Mar 2010 | - | $568.00 K(-96.8%) | $18.09 M(-23.1%) |
| Dec 2009 | $23.52 M(+21.8%) | $17.53 M(<-9900.0%) | $23.52 M(+295.2%) |
| Sep 2009 | - | -$3000.00(+50.0%) | $5.95 M(-10.3%) |
| Jun 2009 | - | -$2000.00(-100.0%) | $6.64 M(+3.4%) |
| Mar 2009 | - | $6.00 M(<-9900.0%) | $6.42 M(-66.8%) |
| Dec 2008 | $19.32 M(+2.4%) | -$41.00 K(-106.0%) | $19.32 M(-0.2%) |
| Sep 2008 | - | $681.00 K(-409.5%) | $19.36 M(-32.5%) |
| Jun 2008 | - | -$220.00 K(-101.2%) | $28.67 M(-0.6%) |
| Mar 2008 | - | $18.90 M(>+9900.0%) | $28.86 M(+52.9%) |
| Dec 2007 | $18.87 M(+536.0%) | $0.00(-100.0%) | $18.87 M(-13.5%) |
| Sep 2007 | - | $10.00 M(<-9900.0%) | $21.83 M(+84.5%) |
| Jun 2007 | - | -$34.00 K(-100.4%) | $11.83 M(-0.4%) |
| Mar 2007 | - | $8.91 M(+201.3%) | $11.88 M(+300.2%) |
| Dec 2006 | $2.97 M(>+9900.0%) | $2.96 M(<-9900.0%) | $2.97 M(>+9900.0%) |
| Sep 2006 | - | -$2000.00(-118.2%) | $23.00 K(0.0%) |
| Jun 2006 | - | $11.00 K(+1000.0%) | $23.00 K(+76.9%) |
| Mar 2006 | - | $1000.00(-92.3%) | $13.00 K(+8.3%) |
| Dec 2005 | $12.00 K(-100.0%) | $13.00 K(-750.0%) | $12.00 K(-80.6%) |
| Sep 2005 | - | -$2000.00(-300.0%) | $62.00 K(-2.7%) |
| Jun 2005 | - | $1000.00(>+9900.0%) | $63.70 K(-99.9%) |
| Mar 2005 | - | $0.00(-100.0%) | $49.45 M(+0.7%) |
| Dec 2004 | $49.09 M(>+9900.0%) | $63.00 K(<-9900.0%) | $49.09 M(+0.1%) |
| Sep 2004 | - | -$300.00(-100.0%) | $49.03 M(-0.0%) |
| Jun 2004 | - | $49.39 M(<-9900.0%) | $49.03 M(<-9900.0%) |
| Mar 2004 | - | -$360.00 K(<-9900.0%) | -$322.40 K(-957.4%) |
| Dec 2003 | $37.60 K | $300.00(>+9900.0%) | $37.60 K(+0.8%) |
| Sep 2003 | - | $0.00(-100.0%) | $37.30 K(0.0%) |
| Jun 2003 | - | $37.30 K(>+9900.0%) | $37.30 K(>+9900.0%) |
| Mar 2003 | - | $0.00 | $0.00 |
FAQ
- What is Corcept Therapeutics Incorporated annual cash flow from financing activities?
- What is the all time high annual CFF for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated annual CFF year-on-year change?
- What is Corcept Therapeutics Incorporated quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated quarterly CFF year-on-year change?
- What is Corcept Therapeutics Incorporated TTM cash flow from financing activities?
- What is the all time high TTM CFF for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated TTM CFF year-on-year change?
What is Corcept Therapeutics Incorporated annual cash flow from financing activities?
The current annual CFF of CORT is -$148.72 M
What is the all time high annual CFF for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high annual cash flow from financing activities is $89.57 M
What is Corcept Therapeutics Incorporated annual CFF year-on-year change?
Over the past year, CORT annual cash flow from financing activities has changed by -$131.44 M (-760.47%)
What is Corcept Therapeutics Incorporated quarterly cash flow from financing activities?
The current quarterly CFF of CORT is -$21.09 M
What is the all time high quarterly CFF for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high quarterly cash flow from financing activities is $76.01 M
What is Corcept Therapeutics Incorporated quarterly CFF year-on-year change?
Over the past year, CORT quarterly cash flow from financing activities has changed by -$20.55 M (-3784.35%)
What is Corcept Therapeutics Incorporated TTM cash flow from financing activities?
The current TTM CFF of CORT is -$23.02 M
What is the all time high TTM CFF for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high TTM cash flow from financing activities is $89.57 M
What is Corcept Therapeutics Incorporated TTM CFF year-on-year change?
Over the past year, CORT TTM cash flow from financing activities has changed by +$126.43 M (+84.60%)